GlassScriptPhysician profile
Hector Gonzalez
NPI 1427120500
$7,328.59
in general payments reported to CMS, 2019-2025
26 companies · $794 in 2025
The $794 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,129 · 2022: $2,232 · 2023: $1,877 · 2024: $1,297 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,967.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,603.45 | 2021-2025 | |
| Janssen Biotech, INC. | $1,076.38 | 2021-2025 | Tremfya |
| Incyte Corporation | $810.80 | 2021-2024 | Opzelura |
| Janssen Scientific Affairs, LLC | $473.42 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $467.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $390.17 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $365.48 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $361.03 | 2022-2025 | Dupixent |
| Genzyme Corporation | $281.72 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $182.36 | 2022-2024 | |
| Allergan, INC. | $161.67 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $148.12 | 2023 | Ycanth |
| Pfizer INC. | $145.03 | 2021-2024 | |
| Dermavant Sciences, INC. | $141.24 | 2022-2023 | Vtama |
| Novartis Pharmaceuticals Corporation | $120.69 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $90.49 | 2022-2025 | Nemluvio |
| Lilly USA, LLC | $85.18 | 2021-2024 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $69.96 | 2022-2025 | |
| Amgen INC. | $68.33 | 2023 | Otezla |
| Leo Pharma INC. | $65.71 | 2022-2024 | Adbry |
| Almirall LLC | $56.36 | 2023-2024 | Klisyri |
| Arcutis Biotherapeutics, INC. | $50.67 | 2023-2024 | Zoryve |
| Mallinckrodt Hospital Products INC. | $45.65 | 2025 | Acthar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.70 | 2025 | Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.92 | 2022 | |
| Organon LLC | $9.51 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.